---
title: "Varegacestat (AL102) in Desmoid tumors: Cryoablation and other local ablative therapies"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Cryoablation and other local ablative therapies. Topics: Local ablative treatments as an alternative to medical therapies, Consensus update of 2023: positioning of local ablative therapies, Cryoablation for small and moderately sized extra-abdominal tumors, Isolated limb perfusion for progressive locally advanced extremity tumors, and 11 further topics. 15 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/cryoablation-and-other-local-ablative-therapies"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Cryoablation and other local ablative therapies

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Cryoablation and Other Local Ablative Therapies

<a id="topic-2.2.2.1.4-1"></a>

### Local ablative treatments as an alternative to medical therapies

> “Local ablative treatments such as cryotherapy or radiotherapy are options that can be considered as an alternative to medical therapies on an individual basis.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.4-2"></a>

### Consensus update of 2023: positioning of local ablative therapies

> “The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.”
> “The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery;”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.1.4-3"></a>

### Cryoablation for small and moderately sized extra-abdominal tumors

> “Cryoablation has been reported in case series to be an effective alternative treatment of small and moderately sized extra-abdominal DF. It is of limited use in patients with larger tumors that can only be partially treated due to the involvement of vital structures.”
> “Of note, both approaches are not available in every center and do require particular expertise.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.4-4"></a>

### Isolated limb perfusion for progressive locally advanced extremity tumors

> “In patients with progressive, locally advanced extremity DF, where resection would result in important functional sacrifice, isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan seems to be a very effective treatment option”
> “With a median follow-up of 7 years, 90% of 25 patients had disease control; of these, 40% developed disease progression after a median of 2 years”
> “This modality can be followed by substantial side effects, although the use of low dose TNF (1 mg) and moderate temperature (never above 39 °C) have made this procedure safer than in the past.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.4-5"></a>

### Cryotherapy in selected patients

> “Cryotherapy may be considered in selected patients to achieve symptom relief and disease control through tumour stabilization or reduction.”
> “Clinical benefit is most likely when at least 50% of the tumour volume is targeted, which may be difficult when the tumour is located near critical structures.”
> “Cryotherapy is a highly specialized procedure and should only be performed by a well-trained expert interventional radiologist.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### CRYODESMO-01 phase II study: design and non-progression rate at 12 months

> “CRYODESMO-01 (ClinicalTrials.gov Identifier: NCT02476305) is a prospective, open-label, non-randomised, non-comparative, multicenter study assessing cryoablation in non-abdominopelvic progressing DT.”
> “The primary end-point was the non-progression rate at 12 months; secondary end-points included safety, quality of life (QoL), assessment of pain and functional status.”
> “50 pts were enrolled (78% female) from four French centres and all were treated.”
> “The median tumour largest diameter was 89 mm. The rate of non-progressing disease at +12 months was 86% [confidence level (CI) 95% 73-94%]. Median PFS was not reached at a median follow-up of 31 months.”

Source: [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/)

<a id="topic-2.2.2.1.4-7"></a>

### CRYODESMO-01 phase II study: toxicity, pain, and function

> “Grade 1 and 2 toxicity occurred in 32.8% and 44.5% of patients, grade 3-4 in 22% and no Grade 5 toxicity was observed. Cryoablation significantly improved functional status and pain scores.”

Source: [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/)

<a id="topic-2.2.2.1.4-8"></a>

### Matched comparison of cryoablation and surgery

> “Twenty-two cryoablation patients were matched with 33 surgical patients (n = 55). Median follow-up after cryoablation was 16.3 months versus 14.9 months after surgery. Two-year local recurrence-free survival (LRFS) was 59% after cryoablation and 71% after surgery, and median LRFS was 26.6 months after cryoablation but was not reached after surgery.”
> “There was no significant difference in LRFS or disease control between matched cryoablation and surgical patients.”

Source: [Mandel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9391920/)

<a id="topic-2.2.2.1.4-9"></a>

### Retrospective study of local recurrence after cryoablation

> “Eighty-four patients treated for nonabdominopelvic desmoid tumors by cryoablation from July 2012 to July 2020 were included in a retrospective study.”
> “Local relapse was found in 19 (22.62%) of 84 patients. The 12-, 24-, and 36-month progression-free survival rates were 89% (95% confidence interval [CI], 79-94), 74% (95% CI, 60-83), and 68% (95% CI, 53-79), respectively.”

Source: [Bouhamama et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37182669/)

<a id="topic-2.2.2.1.4-10"></a>

### Systematic review of cryoablation: response, local progression-free survival, and complications

> “Five studies were included in the systematic review accounting for 146 patients. Only 18.5% patients received cryoablation as a first-line treatment.”
> “Major complications were noted for 13.3-30% patients and following 2.4-6.7% interventional sessions. The rates of complete tumour response ranged between 0 and 43.3%. 1- and 3-year local progression-free survival rates were 85.1-85.8%, and 77.3-82.9%, respectively. Complete pain relief was reported in 40-66.7% symptomatic patients.”

Source: [Cazzato et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35237861/)

<a id="topic-2.2.2.1.4-11"></a>

### Cryoablation in pediatric and young adult patients

> “Twenty-one patients (age 2-22 years; median 14 years), with 21 desmoid tumors, underwent a total of 34 percutaneous cryoablation procedures between August 2013 and August 2023.”
> “According to modified response evaluation criteria in solid tumors (mRECIST), 71%( 15/21) had partial response (PR), 19% (4/21) had complete response (CR), and 10% (2/21) had stable disease. Four (12%) treatments were associated with minor complications, which self-resolved.”

Source: [Shaikh et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39237782/)

<a id="topic-2.2.2.1.4-12"></a>

### Pooled symptom relief and local control across 23 studies of cryoablation, high-intensity focused ultrasound, and microwave ablation

> “After literature selection, 694 DF tumors were identified in 23 studies. In terms of modality, 13 studies used cryoablation, 9 studies used high-intensity focused ultrasound (HIFU), and 1 study used microwave ablation (MWA).”
> “The pooled symptom relief rate was 90% [95% confidence interval (CI): 80–97%], with that for HIFU being 100% (95% CI: 85–100%), that for cryoablation being 87% (95% CI: 74–97%), and that MWA being 89% (95% CI).”
> “In the subgroup analysis, the rate of local control of MWA was 78% (14), that of HIFU was 99% (95% CI: 99–100%), and that of cryoablation was 80% (95% CI: 68–90%), with these differences being statistically significant”

Source: [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/)

<a id="topic-2.2.2.1.4-13"></a>

### Major complications across 694 lesions treated with cryoablation, high-intensity focused ultrasound, or microwave ablation

> “Of the 694 lesions, 40 were associated with major complications, among which severe nerve injury was the most common (26.3%) (Figure 4).”
> “The major complication rates for MWA, HIFU, and cryoablation were 11% (14), 2% (95% CI: 0–6%), and 4% (95% CI: 1–8%), respectively. However, the difference was not statistically significant”

Source: [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/)

<a id="topic-2.2.2.1.4-14"></a>

### Review of high-intensity focused ultrasound in 15 studies of desmoid tumors

> “We review the evidence for high-intensity focused ultrasound (HIFU) in the treatment of soft tissue sarcoma (STS) and desmoid tumour (DT).”
> “We identified 12 studies pertaining to STS (n=178) and 15 studies pertaining to DT (n=417). These were prospective phase I/II open-label trials and retrospective case series or reports. The commonest adverse effects were skin burns, transient pain, and fever. Less common adverse effects of nerve injury and bowel perforation were depended on anatomic relations of the tumour.”
> “There was a high degree of variability in the reporting of outcomes making quantitative analysis challenging.”

Source: [Chetan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40570819/)

<a id="topic-2.2.2.1.4-15"></a>

### Arterial doxorubicin eluting embolization

> “We investigated arterial doxorubicin eluting embolization (DEE), an approach characterized by high drug concentrations in the tumor alongside limited systemic drug exposure.”
> “The study included 24 patients (median age, 24; interquartile range, 16–34 years). Data were collected prospectively for 9 patients and retrospectively for 15 patients.”
> “Of 23 patients, 9 (39%), 12 (52%), and 2 (9%) had a partial response, stable disease, and progressive disease, respectively. DEE was safe and well tolerated, with one reported grade 3–4 adverse event (cord injury).”

Source: [Elnekave et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599870/)

Additional sources: [ClinicalTrials.gov NCT02476305](https://clinicaltrials.gov/study/NCT02476305)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
